Personalizing the treatment of Chronic Pain Patients using the Salonpas® Pain Relieving Patch and Interpretable Artificial Intelligence

Posted on August 11, 2021


Traditionally, prescribed opioid analgesics for treating Chronic Pain can become harmful for the patients and negatively affect their lives. In the meantime, the Chronic Pain condition is affecting the lives of millions of patients deteriorating their ability to perform everyday tasks, diminishing their performance in their work environment and, in general, reducing their satisfaction of life. InSyBio and Clarity Science LLC, capitalizing on their established collaboration, deployed an interpretable artificial intelligence approach to personalize the application of an alternative Chronic Pain treatment based on the Salonpas® Pain Relieving Patch and evaluated their results on a cohort of 186 pain patients. The main findings of this work include:

Peter Hurwitz, President of Clarity Science states: “Being able to incorporate predictive analytics to the treatment decision process, using an artificial intelligence platform like Insybio’s, should allow clinicians and patients to choose, with greater accuracy, personalized and effective treatments that will achieve positive outcomes without needing to trial a medication. This will ultimately lead to a simpler treatment pathway across disciplines that improves patient care through focused prescribing, reduces cost, and limits unnecessary adverse events."


InSyBio-Clarity

This work will be presented at PAINWeek 2021, the National Conference on Pain for Frontline Practitioners, September 7-11, 2021, Las Vegas, USA. Stay tuned with our newsletter to be among the first who will get access to the web tool that will allow the personalization of Chronic Pain treatment with the Salonpas Pain Relieving Patch that will be launched in July 2021.

Read more details on this study in our recent publication:

Gudin J, Mavroudi S, Korfiati A., Dietze, D., & Hurwitz, P. H Personalized Pain Therapy: Artificial Intelligence (AI) Utilized to Predict Patient Response to OTC Topical Analgesics. Anesth Pain Res. 2021; 5 (1): 1-11. Correspondence: Peter Hurwitz, Clarity Science LLC.;750. (https://scivisionpub.com/pdfs/personalized-pain-therapy-artificial-intelligence-ai-utilized-to-predict-patient-response-to-otc-topical-analgesics-1651.pdf)

About InSyBio: InSyBio is an international pioneer bioinformatics revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery and highly-accurate predictive analytics.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models). This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.

About Clarity Science LLC: Clarity Science is an international scientific outcomes research Company assisting biopharmaceutical, specialty pharmacies, and other healthcare Companies with the coordination and execution of scientific, IRB-approved, outcomes studies. Managed by a seasoned staff of healthcare professionals, scientific researchers, outcomes statisticians, and guided by physician experts across multiple therapeutic areas, Clarity Science currently coordinates and administers outcomes studies in pain, allergy, podiatry, scar/wound healing, cardio-metabolic, psychiatry, urology, and genomic testing fields. Whether through improving treatment methodologies or identifying new ones, Clarity aspires to make a global positive impact on patient health and to improve the quality of life for patients and their families. Our goal is to conduct scientifically rigorous and valid research that advances innovation in science and ultimately helps healthcare professionals provide improved patient care, leading to improved patient health worldwide ( www.claritysciences.org )

For any further detail contact our Business Development Manager, Mackenzie Hastings, at m.hastings@insybio.com.


For more News visit our InSyBio Blog.